Cell Reports-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊，SA,NC之类的冲上不去，工作量挺大的，发了cell rep。感觉略亏了，但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向：肠道微生物与宿主互作 经验分享：12月16号投的，23号under review，今天2月14号了，快2个月了，还没有消息，各位一般一审多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津)]

2024-04-30 darktempler 来自江苏省

说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！

2 0

[GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊，SA,NC之类的冲上不去，工作量挺大的，发了cell rep。感觉略亏了，但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向：肠道微生物与宿主互作 经验分享：12月16号投的，23号under review，今天2月14号了，快2个月了，还没有消息，各位一般一审多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津)]

2024-02-07 黑鬼儿来自河北省

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：molecular biology
经验分享：难度不低，影响因子不高，不划算

30 0

[GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊，SA,NC之类的冲上不去，工作量挺大的，发了cell rep。感觉略亏了，但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向：肠道微生物与宿主互作 经验分享：12月16号投的，23号under review，今天2月14号了，快2个月了，还没有消息，各位一般一审多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津)]

2022-06-02 cindichaw

年初接收了一篇。因为顶刊大子刊，SA,NC之类的冲上不去，工作量挺大的，发了cell rep。感觉略亏了，但杂志声望和评审细致都还可以。

157 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊，SA,NC之类的冲上不去，工作量挺大的，发了cell rep。感觉略亏了，但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向：肠道微生物与宿主互作 经验分享：12月16号投的，23号under review，今天2月14号了，快2个月了，还没有消息，各位一般一审多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津)]

2024-01-22 ms2000001775137343 来自安徽省

6月投稿，今年1月接收，历时7个月

33 0

[GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊，SA,NC之类的冲上不去，工作量挺大的，发了cell rep。感觉略亏了，但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向：肠道微生物与宿主互作 经验分享：12月16号投的，23号under review，今天2月14号了，快2个月了，还没有消息，各位一般一审多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津)]

2024-01-17 ms9000001460504456 来自广东省

请问今年影响因子能涨吗？

24 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊，SA,NC之类的冲上不去，工作量挺大的，发了cell rep。感觉略亏了，但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向：肠道微生物与宿主互作 经验分享：12月16号投的，23号under review，今天2月14号了，快2个月了，还没有消息，各位一般一审多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津)]

2023-02-14 朋友一场来自北京

偏重的研究方向：肠道微生物与宿主互作
经验分享：12月16号投的，23号under review，今天2月14号了，快2个月了，还没有消息，各位一般一审多久呀？

115 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊，SA,NC之类的冲上不去，工作量挺大的，发了cell rep。感觉略亏了，但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向：肠道微生物与宿主互作 经验分享：12月16号投的，23号under review，今天2月14号了，快2个月了，还没有消息，各位一般一审多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津)]

2022-03-09 hppv587

二审一个月了还没消息

244 15

展开15条回复

[GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊，SA,NC之类的冲上不去，工作量挺大的，发了cell rep。感觉略亏了，但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向：肠道微生物与宿主互作 经验分享：12月16号投的，23号under review，今天2月14号了，快2个月了，还没有消息，各位一般一审多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津)]

2023-07-13 poiju 来自上海

偏重的研究方向：肿瘤
经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅

186 0

[GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊，SA,NC之类的冲上不去，工作量挺大的，发了cell rep。感觉略亏了，但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向：肠道微生物与宿主互作 经验分享：12月16号投的，23号under review，今天2月14号了，快2个月了，还没有消息，各位一般一审多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津)]

2023-06-14 ms7000001335611101 来自天津

偏重的研究方向：医学;肿瘤
经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢

87 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2201197, encodeId=ecba220119e7a, content=说一下自己的被坑遭遇，投了cell reports，一审被拒，然后argue后给了大修，二审被拒，三个审稿人，二审时另外两个都没意见了，就被其中一个审稿人给恶心了。我做的是蛋白的乳酸化修饰机制，通用的做法都是把赖氨酸(K)突变成精氨酸（R）来模拟去修饰状态，这个审稿人就是不认可，第一次拒稿也是因为他质疑这个氨基酸突变模拟，如果他不认可这个氨基酸突变的模拟，那我所有的工作就都是空中楼阁了。不谈其他杂志了，cell主刊都发了好几篇乳酸化修饰的文章了，都是这么做的，并且我的文章还排除了这个位点其他可能存在的占主导优势的赖氨酸酰化修饰，cell文章里都没我这么严谨！这些编辑没点自己的判断吗，就这么维护审稿人的傻逼意见，真的很无语！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Tue Apr 30 09:44:30 CST 2024, time=2024-04-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2186331, encodeId=cf2e2186331f6, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：molecular biology 经验分享：难度不低，影响因子不高，不划算, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a552358842, createdName=黑鬼儿, createdTime=Wed Feb 07 11:51:41 CST 2024, time=2024-02-07, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=1224046, encodeId=a58e12240467c, content=年初接收了一篇。因为顶刊大子刊，SA,NC之类的冲上不去，工作量挺大的，发了cell rep。感觉略亏了，但杂志声望和评审细致都还可以。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Thu Jun 02 15:00:38 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183140, encodeId=e78f218314022, content=6月投稿，今年1月接收，历时7个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22458475435, createdName=ms2000001775137343, createdTime=Mon Jan 22 10:54:10 CST 2024, time=2024-01-22, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2114571, encodeId=6f6921145e1ca, content=偏重的研究方向：肠道微生物与宿主互作 经验分享：12月16号投的，23号under review，今天2月14号了，快2个月了，还没有消息，各位一般一审多久呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcea1641911, createdName=朋友一场, createdTime=Tue Feb 14 14:00:57 CST 2023, time=2023-02-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1201019, encodeId=cca212010196f, content=二审一个月了还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae622062117, createdName=hppv587, createdTime=Wed Mar 09 20:09:57 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2147882, encodeId=da44214e88293, content=偏重的研究方向：肿瘤 经验分享：文章质量很好，不明白为什么一直上不去10呢？难道是不怎么发综述吗？很多文章明显比有的10+期刊还好😅, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48ef2508535, createdName=poiju, createdTime=Thu Jul 13 18:40:43 CST 2023, time=2023-07-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2142783, encodeId=54ee2142e83cc, content=偏重的研究方向：医学;肿瘤 经验分享：请问under review是送审了吗？为什么没收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 19:05:14 CST 2023, time=2023-06-14, status=1, ipAttribution=天津)]

2023-06-14 ms7000001335611101 来自天津

偏重的研究方向：医学;肿瘤
经验分享：请问under review是送审了吗？为什么没收到邮件呢

91 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务